October 05, 2026
Short answer: Exosomes are tiny membrane-bound packets that cells release to signal to other cells, carrying proteins, lipids and genetic material such as microRNA. In skincare they are usually harvested from cultured human stem cells, or from plants and other sources. No exosome product is approved as a drug in the United States, and in Canada a topical exosome product can be sold as a cosmetic only if it makes cosmetic claims and is not meant to be needled or injected. The human evidence for benefit is early and of low certainty.
Exosomes are a subtype of extracellular vesicles (EVs): lipid-bilayer particles roughly 30 to 150 nanometres across that form inside cells and are released to deliver their cargo to neighbouring cells. The idea behind using them on skin is that vesicles from stem cells carry signals that dampen inflammation, support new blood vessels and push fibroblasts to rebuild matrix. A 2026 review points out that many aesthetic products and studies call their preparations "exosomes" without showing that the vesicles actually came from the endosomal pathway that defines an exosome; most are better described as mixed small EVs (Contreras 2026).
Sources differ widely. Products may use vesicles from human adipose, bone marrow or umbilical cord stem cells, from human cell-conditioned media (the liquid cells were grown in), or from plants such as rose or from animals such as salmon. A label saying "exosomes" tells you little about the source, the dose, how the vesicles were purified, or whether they are intact by the time the bottle is opened. Reviews name this lack of standardization in production and application as the main brake on the field (Shah 2025).
In the United States, the FDA's position since its 2019 public safety notification is that there are no FDA-approved exosome products and that exosome products intended to treat diseases or conditions require FDA approval as drugs and biological products. That notification followed reports of serious adverse events in Nebraska patients treated with unapproved products marketed as containing exosomes.
In Canada, Health Canada's final notice on topical products containing human-derived exosomes, extracellular vesicles or cell-conditioned media, which followed an August 2025 consultation, sets out three tests. Based on the evidence to date, these ingredients are not inherently drugs, so a product can be a cosmetic or a drug depending on how it is presented and used. Claims to treat, prevent or mitigate disease, or to have therapeutic, pharmacological or biological effects, make it a drug. A product whose label or instructions say to apply it by microneedling or injection is not consistent with a cosmetic. A composition with therapeutic or pharmacological activity is not a cosmetic either.
The practical meaning for you: an exosome serum sold as a cosmetic in Canada is approved for nothing. It has met cosmetic rules, which concern safety and labelling, not evidence that it rebuilds collagen. And the common clinic practice of spreading an exosome product over freshly needled skin falls outside what a cosmetic is for.
The best summary so far is a 2026 Canadian systematic review of EV therapies for nonsurgical facial rejuvenation. It found 16 studies with 503 participants in total, a mix of split-face, comparative and single-arm designs. Most reported improvement in at least one outcome such as wrinkles, pigmentation, hydration or elasticity, and comparative studies generally favoured the EV-treated side. But risk of bias was moderate to critical for most outcomes and certainty of evidence was rated low or very low (Gaebe 2026). Where vesicles are applied after microneedling or another procedure, as in many published protocols, the effect of the procedure and the effect of the vesicles are hard to separate.
For a serum on intact skin, the question is penetration. Vesicles are thousands of times larger than the molecules that pass through healthy stratum corneum easily, and how much reaches living cells through intact skin has not been established in people. A well-made exosome serum may still feel pleasant and hydrating; that is a property of the formula, not proof of vesicle signalling.
On intact skin, the realistic risks resemble those of any serum: irritation or allergy to the base, the preservative or a botanical. Multi-component biological mixtures add one difficulty. If you react, you cannot tell which component caused it, which is the reason to patch test, not a sign that the vesicles are uniquely allergenic.
The serious reports involve injection or broken skin. The Gaebe review found no serious adverse events within its trials, but trials are small and short (Gaebe 2026). Outside trials, a 2026 report from the Massachusetts General Hospital laser and cosmetic centre describes a persistent skin reaction after facial exosome injections and microneedling (Myers 2026), and reviewers cite adverse reactions linked to unapproved products marketed as exosome formulations (Contreras 2026). This fits the wider microneedling literature: granulomatous reactions are among the persistent serious adverse events, and caution is advised when needling is combined with products not approved for intradermal use (Chu 2021).
Exosomes sit in the same evidence tier as other biologic actives such as PDRN; the evidence on PDRN shows the same gap between injected and topical use. If what you want is firmer skin, the foundations of anti-ageing care rest on far stronger data.
See a physician or dermatologist for lumps, nodules, persistent redness or swelling that last more than a week or two after any treatment involving exosomes, and urgently for heat, spreading redness, pus, fever or pain that is increasing rather than settling. Bring the product name and lot number if you have them. If you have had skin cancer, are immunosuppressed, or are pregnant or breastfeeding, ask your physician before any exosome treatment; there are no data for these groups.
Less than marketing suggests. The trials are small and short, often combined with procedures, use different vesicle sources and doses, and are rated low to very low certainty. Mechanism data come largely from cell and animal studies. Two of the sources here, the MGH report and the reviewers' safety comments, show that adverse reactions occur but cannot tell us how often. The regulatory statements describe US and Canadian positions at the time of writing and may change. This article is for education only; it is not a diagnosis and not a substitute for advice from a physician or dermatologist.
Literature retrieved from PubMed.
Clara Song is the founder and in-house formulator of COMPLETE ELIXIR, and judging what an ingredient can and cannot do is her daily work; you can read more about her on the founder page. If you are weighing an exosome serum or a clinic treatment, send her the product name, the full ingredient list and what was promised, and she will tell you plainly what the evidence supports. Email info@completeelixir.com.
For a broader guide and related questions, visit the Skincare Ingredient Tolerance Resource Centre.
Written and reviewed by Clara Song, Ph.D.
Founder and in-house formulator, COMPLETE ELIXIR
Ph.D. in Data Science · Medical Aesthetician Diploma
Last reviewed: October 5, 2026
This article distinguishes ingredient evidence, formulation rationale, finished-product evidence and professional observation. It is educational and does not replace medical diagnosis or treatment.
October 07, 2026
October 07, 2026
October 07, 2026
